Changxian Li
Dalian Jiaotong University(CN)
Publications by Year
Research Areas
Cholangiocarcinoma and Gallbladder Cancer Studies, Peptidase Inhibition and Analysis, Hepatocellular Carcinoma Treatment and Prognosis, Cancer-related molecular mechanisms research, RNA modifications and cancer
Most-Cited Works
- → Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial(2020)158 cited
- → Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth(2013)112 cited
- → Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma(2022)102 cited
- → Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization(2019)85 cited
- → The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers(2022)62 cited
- → The lncRNA Gm15622 stimulates SREBP-1c expression and hepatic lipid accumulation by sponging the miR-742-3p in mice(2020)55 cited
- → Single‐cell profiling of human CD127+ innate lymphoid cells reveals diverse immune phenotypes in hepatocellular carcinoma(2022)48 cited
- → Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study(2022)47 cited
- → KIF14 promotes proliferation, lymphatic metastasis and chemoresistance through G3BP1/YBX1 mediated NF-κB pathway in cholangiocarcinoma(2023)41 cited
- → Fusion with stem cell makes the hepatocellular carcinoma cells similar to liver tumor-initiating cells(2016)37 cited